Vyome Holdings (HIND) Interest Expenses (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Interest Expenses of $144419.0 for Q1 2026, up 23.54% year-over-year from $116900.0 in Q1 2025, and up 385.59% quarter-over-quarter from $29741.0 in Q4 2025.
Vyome Holdings (HIND) Interest Expenses (2015 - 2026) Analysis & Trends
Vyome Holdings' Interest Expenses history runs 12 years deep, the most recent figure standing at $144419.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 23.54% year-over-year to $144419.0; the TTM figure through Mar 2026 stood at $316664.0 (down 35.14% YoY), while the FY2025 annual figure was $75.2 million, up 850.64% from the prior year.
- Interest Expenses for Q1 2026 stood at $144419.0, up from $29741.0 in the prior quarter.
- The five-year high for Interest Expenses was $347000.0 in Q2 2022, with the low at $25604.0 in Q3 2025.
- The 5-year median for Interest Expenses is $116900.0 (2025), against an average of $145588.8.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses jumped 1827.78% in 2022, then plunged 90.4% in 2025.
- Vyome Holdings' Interest Expenses stood at $87000.0 in 2022, then tumbled by 37.93% to $54000.0 in 2023, then slipped by 6.39% to $50551.0 in 2024, then tumbled by 41.17% to $29741.0 in 2025, then surged by 385.59% to $144419.0 in 2026.
- Business Quant data shows HIND's Interest Expenses at $144419.0 in Q1 2026, $29741.0 in Q4 2025, and $25604.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 3,325.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142,883.00 |
| Jun 30, 2026 | 142,883.00 |
| Mar 31, 2026 | 144,419.00 |
| Mar 31, 2026 | 144,419.00 |
| Dec 31, 2025 | 29,741.00 |
| Dec 31, 2025 | 29,741.00 |
| Sep 30, 2025 | 25,604.00 |
| Sep 30, 2025 | 25,604.00 |
| Jun 30, 2025 | 118,000.00 |
| Jun 30, 2025 | 118,000.00 |
| Mar 31, 2025 | 116,900.00 |
| Mar 31, 2025 | 116,900.00 |
| Dec 31, 2024 | 50,551.00 |
| Dec 31, 2024 | 50,551.00 |
| Sep 30, 2024 | 266,794.00 |
| Sep 30, 2024 | 266,794.00 |
| Jun 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 231,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |